Abstract
Tau pathology, neuroinflammation, and neurodegeneration are key aspects of Alzheimer’s disease. Understanding whether these features predict cognitive decline, alone or in combination, is crucial to develop new prognostic measures and enhanced stratification for clinical trials. Here, we studied how baseline assessments of in vivo tau pathology (measured by [18F]AV-1451 PET), neuroinflammation (indexed via [11C]PK11195 PET) and brain atrophy (derived from structural MRI) predicted longitudinal cognitive changes in patients with Alzheimer’s disease pathology. Twenty-six patients (n=12 with clinically probable Alzheimer’s dementia and n=14 with amyloid positive Mild Cognitive Impairment) and 29 healthy controls underwent baseline assessment with [18F]AV-1451 PET, [11C]PK11195 PET, and structural MRI. Cognition was examined annually over the subsequent 3 years using the revised Addenbrooke’s Cognitive Examination. Regional grey-matter volumes, [18F]AV-1451 and [11C]PK11195 binding were derived from fifteen temporo-parietal regions characteristically affected by Alzheimer’s disease pathology. A Principal Component Analysis (PCA) was used on each imaging modality separately, to identify the main spatial distributions of pathology. A Latent Growth Curve model was applied across the whole sample on longitudinal cognitive scores to estimate the rate of annual decline in each participant. We regressed the individuals’ estimated slope of cognitive decline on the neuroimaging components and examined univariable models with single-modality predictors, and a multi-modality model of prediction, to identify the independent and combined prognostic value of the different neuroimaging markers.
PCA identified a single component for the grey-matter atrophy, while two components were found for each PET ligand: one weighted to the anterior temporal lobe, and another weighted to posterior temporo-parietal regions. Across the whole-sample, the single-modality models indicated significant correlations between the slope of cognitive decline and the first component of each imaging modality. In patients, both stepwise backward elimination and Bayesian model selection revealed an optimal predictive model that included both components of [18F]AV-1451 and the first (i.e., anterior temporal) component for [11C]PK11195. However, the MRI-derived atrophy component and demographic variables were excluded from the optimal predictive model of cognitive decline. We conclude that temporo-parietal tau pathology and anterior temporal neuroinflammation predict cognitive decline in patients with symptomatic Alzheimer’s disease pathology. This indicates the added value of PET biomarkers in predicting cognitive decline in Alzheimer’s disease, over and above MRI measures of brain atrophy and demographic data. Our findings also support the strategy for targeting tau and neuroinflammation in disease-modifying therapy against Alzheimer’s Disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration theme; the Wellcome Trust (JBR 103838); the Cambridge Trust & Sidney Sussex College Scholarship (MM); the Medical Research Council (RAK: SUAG/014 RG91365; and LP: MR/P01271X/1); the Cambridge centre for Parkinson plus (SPJ, TR), and the British Academy Postdoctoral Fellowship (KAT: PF160048). JBR reports consultancy unrelated to the work with Biogen, UCB, Asceneuron and Althira; and recipt of research grants from Janssen, AZ-Medimmune, Lilly unrelated to this work. JOB has provided consultancy to TauRx, Axon, Roche, GE Healthcare, Lilly and has research awards from Alliance Medical and Merck. Acknowledgments We thank our participant volunteers for their participation in this study, and the radiographers/technologists at the Wolfson Brain Imaging Centre and Addenbrooke’s PET/CT Unit, and the research nurses of the Cambridge Centre for Frontotemporal Dementia and Related Disorders for their invaluable support in data acquisition. We thank the East Anglia Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) for help with subject recruitment, and Drs Istvan Boros, Joong-Hyun Chun, and other WBIC RPU staff for the manufacture of the radioligands. We thank Avid (Lilly) for supplying the precursor for the production of [18F]AV-1451 used in this study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymized data may be shared by request to the senior author from a qualified investigator for non-commercial use (data sharing is subject to participants’ prior consent to data sharing).
